Linked Life Data

11029334

Source:http://linkedlifedata.com/resource/pubmed/id/11029334

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4 Pt 1
pubmed:dateCreated
2000-11-15
pubmed:abstractText
To compare the antiasthmatic efficacy of inflammatory mediator blockade versus topical corticosteroid therapy in patients with seasonal allergic rhinitis (SAR) and asthma, 14 patients were enrolled into a single-blind, double-dummy, placebo-controlled crossover study comparing 2 wk therapy of (1) 400 microgram orally inhaled budesonide plus 200 microgram intranasal budesonide (BUD) or (2) 10 mg oral montelukast plus 10 mg oral cetirizine (ML + CZ). Before each treatment period, patients received 7 to 10 d placebo washout. All treatments were given once daily in the morning. Throughout the study, patients recorded the following domiciliary measures: peak expiratory flow (PEF), rescue inhaler requirement, asthma symptoms, and daily activity score. Laboratory measurements were made at trough of adenosine monophosphate (AMP) bronchial challenge and exhaled nitric oxide (NO). Compared with pooled placebo (PL), there were significant (p < 0.05) improvements in all domiciliary measures with both treatments (mean PEF [L/min] PL: 463; BUD: 478; ML + CZ: 483). For geometric mean AMP PC(20) (mg/ml), there was an improvement (p < 0.05), compared with PL (47), for ML + CZ (133) but not for BUD (51); whereas for NO (ppb) there was significant suppression with BUD (7.6) but not ML + CZ (11.5) compared with PL (13.6). In conclusion, both combined mediator blockade and combined topical corticosteroids are equally effective antiasthma therapy in patients with asthma and SAR.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1073-449X
pubmed:author
pubmed:issnType
Print
pubmed:volume
162
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1297-301
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:11029334-Acetates, pubmed-meshheading:11029334-Administration, Inhalation, pubmed-meshheading:11029334-Administration, Oral, pubmed-meshheading:11029334-Anti-Asthmatic Agents, pubmed-meshheading:11029334-Asthma, pubmed-meshheading:11029334-Bronchial Provocation Tests, pubmed-meshheading:11029334-Budesonide, pubmed-meshheading:11029334-Cetirizine, pubmed-meshheading:11029334-Cross-Over Studies, pubmed-meshheading:11029334-Double-Blind Method, pubmed-meshheading:11029334-Drug Therapy, Combination, pubmed-meshheading:11029334-Forced Expiratory Volume, pubmed-meshheading:11029334-Humans, pubmed-meshheading:11029334-Inflammation Mediators, pubmed-meshheading:11029334-Leukotriene Antagonists, pubmed-meshheading:11029334-Quinolines, pubmed-meshheading:11029334-Rhinitis, Allergic, Seasonal
pubmed:year
2000
pubmed:articleTitle
Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma.
pubmed:affiliation
Asthma and Allergy Research Group, Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't